Publications by authors named "Dina Michael"

Claim this Profile
D
Downstream STING pathways IRF3 and NF-κB differentially regulate CCL22 in response to cytosolic dsDNA.
Jihyun Kim, Jocelyn V Pena, Hannah P McQueen, Lingwei Kong, Dina Michael

Cancer Gene Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GDC-0449-a potent inhibitor of the hedgehog pathway.
Kirk D Robarge, Shirley A Brunton, Georgette M Castanedo, Yong Cui, Michael S Dina, Michael F T Koehler

Bioorg Med Chem Lett· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.
Banavara L Mylari, Sandra J Armento, David A Beebe, Edward L Conn, James B Coutcher, Michael S Dina, Michael C Linhares

J Med Chem· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one.
Banavara L Mylari, Sandra J Armento, David A Beebe, Edward L Conn, James B Coutcher, Michael S Dina, Michael C Linhares

J Med Chem· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis